JP2015506698A - 多能性胚葉起源抗原を提示する癌ワクチン - Google Patents

多能性胚葉起源抗原を提示する癌ワクチン Download PDF

Info

Publication number
JP2015506698A
JP2015506698A JP2014555705A JP2014555705A JP2015506698A JP 2015506698 A JP2015506698 A JP 2015506698A JP 2014555705 A JP2014555705 A JP 2014555705A JP 2014555705 A JP2014555705 A JP 2014555705A JP 2015506698 A JP2015506698 A JP 2015506698A
Authority
JP
Japan
Prior art keywords
cells
cancer
inf
cell
melanoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014555705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015506698A5 (enExample
Inventor
アンドリュー コーンフォース
アンドリュー コーンフォース
ロバート ディルマン
ロバート ディルマン
Original Assignee
カリフォルニア ステム セル インコーポレイテッド
カリフォルニア ステム セル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カリフォルニア ステム セル インコーポレイテッド, カリフォルニア ステム セル インコーポレイテッド filed Critical カリフォルニア ステム セル インコーポレイテッド
Publication of JP2015506698A publication Critical patent/JP2015506698A/ja
Publication of JP2015506698A5 publication Critical patent/JP2015506698A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2014555705A 2012-02-02 2013-01-31 多能性胚葉起源抗原を提示する癌ワクチン Pending JP2015506698A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261594304P 2012-02-02 2012-02-02
US61/594,304 2012-02-02
PCT/US2013/024123 WO2013116505A1 (en) 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine

Publications (2)

Publication Number Publication Date
JP2015506698A true JP2015506698A (ja) 2015-03-05
JP2015506698A5 JP2015506698A5 (enExample) 2017-08-24

Family

ID=48905824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014555705A Pending JP2015506698A (ja) 2012-02-02 2013-01-31 多能性胚葉起源抗原を提示する癌ワクチン

Country Status (13)

Country Link
US (1) US20150064217A1 (enExample)
EP (1) EP2809775B1 (enExample)
JP (1) JP2015506698A (enExample)
KR (1) KR20140143361A (enExample)
CN (1) CN104540937A (enExample)
AU (1) AU2013215116A1 (enExample)
CA (1) CA2863653A1 (enExample)
GB (1) GB2512558A (enExample)
HK (2) HK1209455A1 (enExample)
IL (1) IL233928A0 (enExample)
NZ (1) NZ628292A (enExample)
SG (1) SG11201404543UA (enExample)
WO (2) WO2013116541A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018131659A1 (ja) * 2017-01-11 2018-07-19 国立研究開発法人国立がん研究センター 免疫療法剤

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103599528B (zh) * 2013-12-04 2015-08-05 深圳市合一康生物科技股份有限公司 人树突状细胞疫苗的制备方法
JP6423889B2 (ja) 2014-10-07 2018-11-14 サイトリミック株式会社 Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
EP3527216B1 (en) 2016-10-11 2024-02-14 NEC Corporation A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide
EP3582793A4 (en) * 2017-02-17 2020-12-16 Aivita Biomedical, Inc. METHODS TO IMPROVE TUMOR IMMUNOGENICITY AND COMPOSITIONS FOR AUTOLOGOUS ANTI-CANCER IMMUNOTHERAPEUTICS USING MODIFIED TUMOR CELLS AND MODIFIED DENDRITIC CELLS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008517946A (ja) * 2004-10-25 2008-05-29 ベイラー・リサーチ・インスチチユート 熱ショックをかけたメラノーマ細胞体が装填された樹状細胞
JP2009502955A (ja) * 2005-07-29 2009-01-29 プロビデンス ヘルス システム 小胞（ｄｒｉｂｂｌｅ）中の不完全なリボソーム産物、および免疫応答を刺激するための使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140796A0 (en) * 2001-01-08 2002-02-10 Hadasit Med Res Service An autologous anti-cancer vaccine
EP2322603B1 (en) * 2001-09-06 2019-10-16 NorthWest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and T cells for Th1 response
WO2008039974A2 (en) * 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US20090041792A1 (en) * 2007-07-19 2009-02-12 Istituto Superiore Di Sanita Dendritic cells, uses therefor, and vaccines and methods comprising the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008517946A (ja) * 2004-10-25 2008-05-29 ベイラー・リサーチ・インスチチユート 熱ショックをかけたメラノーマ細胞体が装填された樹状細胞
JP2009502955A (ja) * 2005-07-29 2009-01-29 プロビデンス ヘルス システム 小胞（ｄｒｉｂｂｌｅ）中の不完全なリボソーム産物、および免疫応答を刺激するための使用方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2011, 26(3):345-351, JPN6016036936, ISSN: 0003473495 *
CANCER CELL, 2008, 68(17):6889-6895, JPN6016036935, ISSN: 0003473496 *
DILLMAN RO ET AL., PHASE II TRIAL OF DENDRITIC CELLS LOADED WITH ANTIGENS FROM SELF-RENEWING, PROLIF, JPN6017046763, ISSN: 0003696236 *
LI Y ET AL., EFFICIENT CROSS-PRESENTATION DEPENDS ON AUTOPHAGY IN TUMOR CELLS, CANCER RES. [ONLINE],, JPN6017046759, ISSN: 0003696235 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018131659A1 (ja) * 2017-01-11 2018-07-19 国立研究開発法人国立がん研究センター 免疫療法剤
JPWO2018131659A1 (ja) * 2017-01-11 2019-12-12 国立研究開発法人国立がん研究センター 免疫療法剤

Also Published As

Publication number Publication date
IL233928A0 (en) 2014-09-30
WO2013116505A1 (en) 2013-08-08
GB201414403D0 (en) 2014-10-01
CN104540937A (zh) 2015-04-22
SG11201404543UA (en) 2014-08-28
US20150064217A1 (en) 2015-03-05
NZ628292A (en) 2016-09-30
EP2809775A4 (en) 2015-07-01
HK1202432A1 (en) 2015-10-02
GB2512558A (en) 2014-10-01
KR20140143361A (ko) 2014-12-16
CA2863653A1 (en) 2013-08-08
HK1209455A1 (en) 2016-04-01
EP2809775A1 (en) 2014-12-10
EP2809775B1 (en) 2018-06-13
WO2013116541A1 (en) 2013-08-08
AU2013215116A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
Navabi et al. A clinical grade poly I: C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro
Palucka et al. Recent developments in cancer vaccines
JP6134763B2 (ja) ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞
US9555058B2 (en) Antigen presenting cancer vaccine
US8097242B2 (en) Target CA125 peptides for cancer immunotherapy
JP2015506698A (ja) 多能性胚葉起源抗原を提示する癌ワクチン
Flores et al. Dendritic Cells Loaded with Heat Shock‐Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell‐Dependent Antitumor Immune Responses In Vitro
Nguyen-Pham et al. Immunotherapy using dendritic cells against multiple myeloma: how to improve?
HK1230080A1 (en) Antigen presenting cancer vaccine with gamma interferon
US10716810B2 (en) Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytes
NZ623917B2 (en) Antigen presenting cancer vaccine
Cantrell Adjuvant effect of chaperone-rich cell lysate: the effects of CRCL on the activation of immune cells
Roomi et al. Regulation of MMP-2 and MMP-9 Expression in Childhood Osteosarcoma by Inducers and Inhibitors

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20150302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150302

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20160113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170707

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171206

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20180216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180216

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180306

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180813